Emerging therapies in PAH and scleroderma-related PAH

G. Simonneau (Clamart, France)

Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension

Number: 9

Disease area: Pulmonary vascular diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Simonneau (Clamart, France). Emerging therapies in PAH and scleroderma-related PAH. Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Upfront combination PAH therapy in severe PAH Source: International Congress 2014 – Combination therapy in pulmonary arterial hypertension (PAH): the evidence grows Year: 2014
Applying pharmacogenomics to pulmonary arterial hypertension (PAH): A target-based approach to therapy Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
Emerging drugs in chronic obstructive pulmonary disease Source: Annual Congress 2010 - Emerging drugs in COPD Year: 2010
Determinants of survival in scleroderma-related PAH Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension Year: 2008
Potential pharmacological interactions between oral pulmonary arterial hypertension (PAH) therapies and new oral anticoagulants Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012
Response to increased load in systemic sclerosis-associated PAH and idiopathic PAH Source: Annual Congress 2013 –Pulmonary circulation: clinical physiology Year: 2013
Novel therapeutic perspectives in pulmonary arterial hypertension Source: Eur Respir J 2003; 22: 193-194 Year: 2003
Emerging models of pulmonary rehabilitation Source: Eur Respir Monogr 2021; 93: 294-310 Year: 2021
Response to PAH specific therapy in systemic sclerosis patients with extensive parenchymal changes and pulmonary hypertension Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020
Epidemiological and Clinical aspects of pulmonary arterial hypertension (PAH) Source: International Congress 2018 – Clinical aspects of pulmonary hypertension Year: 2018
New horizons in pulmonary arterial hypertension therapies Source: Eur Respir Rev 2013; 22: 503-514 Year: 2013
Current strategies for managing CTEPH Source: Virtual Congress 2021 – Non-pulmonary arterial hypertension pulmonary hypertension Year: 2021
Pharmacological actions of statins: potential utility in COPD Source: Eur Respir Rev 2009; 18: 222-232 Year: 2009
Novel biomarkers in idiopathic pulmonary arterial hypertension Source: Annual Congress 2010 - Pulmonary hypertension Year: 2010
Emerging anti-inflammatory strategies for COPD}, Source: Eur Respir J 2012; 40: 724-741 Year: 2012